Braham Shroot

Dr. Braham Shroot has more than 35 years of hands-on experience in drug research and development, specializing in novel aesthetic biologic products for skin disorders including acne, rosacea, psoriasis, atopic dermatitis fungal infections, and chronic skin ulcers. As an R&D expert, he consults with biotech, pharmaceutical, and biopharma companies on a wide range of acute and chronic skin disorders, including rare diseases.

Dr. Shroot was formerly the chief executive officer at Signum Biosciences/Argyle Therapeutics, a private biotechnology company dedicated to developing small molecule therapeutics for dermatological applications. Previously, he was the chief scientific officer of Barrier Therapeutics, which was acquired by Stiefel Laboratories in August 2008. Dr. Shroot was also the chief scientific officer and vice president of R&D for DFB Pharmaceuticals, a fully integrated private specialty pharmaceutical company with a focus on the skin, wound care, and surgical markets.